Over the past decade, the pet supplement category has evolved rapidly, fueled by the growing humanization of pets and rising expectations from pet owners who increasingly view dogs and cats as family members. While this evolution has driven innovation, it has also exposed important scientific, regulatory, and methodological gaps between pet supplements and human dietary supplements—gaps that ingredient suppliers, formulators, veterinarians, and brands must address together.

One of the most significant scientific gaps lies in the depth and robustness of clinical evidence available for pets. Human dietary supplements benefit from decades of accumulated clinical research, standardized endpoints, and validated biomarkers. In contrast, pet supplement development often relies on extrapolated data, small-scale trials, or observational studies. There is a clear need for more species-specific pharmacokinetic, bioavailability, and efficacy data to better understand how active ingredients behave in different companion animals, particularly across breeds, ages, and life stages.

This leads directly to the importance of species-specific research. Dogs and cats differ not only from humans but also from each other in metabolism, digestive physiology, microbiota composition, and nutrient requirements. While human data can be useful for initial ingredient screening or safety assessment, it is rarely sufficient on its own to substantiate pet-specific claims. Human studies may help explain a mechanism of action, but without confirming absorption, metabolism, and functional outcomes in the target species, there is a risk of overpromising benefits that may not translate clinically. Responsible ingredient development therefore requires at least some level of species-relevant validation, even if it begins with pilot or exploratory studies.

The humanization of pets has undoubtedly helped raise awareness around ingredient quality, formulation science, and preventive health. Pet owners are now more interested in antioxidants, probiotics, omega fatty acids, and botanical extracts than ever before. However, this trend also carries the risk of unrealistic expectations. Consumers may assume that a pet supplement will deliver the same magnitude or speed of benefit as a human supplement, despite differences in physiology and clinical endpoints. Managing this expectation gap requires transparent communication, realistic claims, and education around what supplements can—and cannot—reasonably deliver.

From an ingredient supplier’s perspective, quality parameters are foundational, but their relative importance can differ slightly in pet applications. Standardization is critical to ensure batch-to-batch consistency, particularly for botanical extracts where natural variability is inherent. Bioavailability is equally important, as an ingredient’s theoretical potency is irrelevant if it is poorly absorbed or rapidly metabolized in the target species. Purity and contaminant control—especially for heavy metals, pesticide residues, and solvent residues—are non-negotiable, not only for regulatory compliance but also for long-term animal safety. Increasingly, ingredient suppliers are also expected to provide detailed documentation, traceability, and analytical validation to support these quality claims.

Broader consumer trends such as clean label, sustainability, and transparency are now strongly influencing purchasing decisions in the pet supplement space. Pet owners are scrutinizing ingredient lists, favoring recognizable, minimally processed ingredients, and questioning artificial additives or synthetic actives. Sustainability considerations—such as responsibly sourced botanicals, reduced environmental impact, and ethical supply chains—are no longer “nice to have” but are becoming part of brand trust. Transparency, including clear labeling, accessible technical explanations, and openness about sourcing and manufacturing, is increasingly viewed as a marker of credibility.

When it comes to clinical evidence, expectations must remain realistic. Unlike pharmaceuticals, pet supplements are not designed to diagnose, treat, or cure disease. Therefore, the most appropriate evidence often comes from a combination of in vitro data, preclinical models, pilot animal studies, and well-designed observational or field trials. Randomized, controlled studies in companion animals are ideal, but they are expensive, time-consuming, and logistically complex. Still, even smaller studies with clearly defined endpoints, proper controls, and transparent reporting can significantly strengthen claim substantiation.

Certain types of claims are particularly prone to consumer misunderstanding, especially those related to inflammation, immunity, cognition, and longevity. Terms such as “anti-inflammatory,” “immune boosting,” or “anti-aging” can easily be interpreted as disease-related or curative. To reduce this risk, claims should be framed around structure–function language, such as “supports joint comfort,” “helps maintain normal immune function,” or “supports healthy ageing.” Clear substantiation summaries and educational materials can further help align consumer perception with scientific reality.

Conducting clinical trials in companion animals presents unique methodological challenges. Variability in breed, size, diet, environment, and lifestyle can introduce significant noise into study outcomes. Compliance is another challenge, as dosing often depends on pet owner consistency. These issues can be mitigated through careful study design, including adequate sample sizes, stratification where possible, standardized feeding protocols, and clear owner instructions. Collaboration with veterinary clinics and academic institutions can also improve study rigor and data quality.

A related challenge is the reliance on owner-reported outcomes. While subjective assessments can introduce bias, they are also highly relevant, as pet owners are often the first to notice changes in mobility, behavior, appetite, or coat quality. Owner-reported outcomes should not be dismissed; instead, they should be integrated thoughtfully alongside objective veterinary assessments, biomarkers, or functional measurements. When aligned properly, these complementary data sources can provide a more holistic view of supplement impact.

Finally, there is a clear and growing interest in ingredients formulated to promote healthy ageing in pets. Antioxidant-rich botanicals, omega-3 fatty acids, joint-support ingredients, gut health modulators, and cognitive-support actives are increasingly common. This trend reflects both demographic shifts—pets living longer lives—and owner interest in preventive, long-term wellness strategies. From an ingredient supplier standpoint, this area represents a significant opportunity, provided that innovation is grounded in sound science, realistic claims, and transparent communication.

In conclusion, the future of pet supplement development depends on narrowing the clinical evidence gap while maintaining a pragmatic, species-appropriate approach to innovation. Ingredient suppliers play a central role in this process by delivering high-quality, well-characterized actives and supporting them with credible, relevant data. By aligning scientific rigor with consumer expectations and ethical responsibility, the industry can continue to grow while earning lasting trust from veterinarians and pet owners alike. 

4A) Over the next 5–10 years, the credibility and long-term success of the pet supplements sector will be determined by a combination of scientific rigor, transparency, and alignment with veterinary practice. As the category matures, growth will no longer be driven primarily by novelty or emotional marketing, but by the industry’s ability to demonstrate that products are safe, consistent, and meaningfully supportive of animal health.

One of the most decisive factors will be the quality of evidence behind ingredients and claims. This does not necessarily mean pharmaceutical-level trials for every product, but it does require a clear step forward from anecdotal support toward structured, species-relevant data. Brands and ingredient suppliers that invest in standardized ingredients, reproducible manufacturing, and well-designed studies—whether clinical, observational, or mechanistic—will stand apart from those relying solely on borrowed human data or marketing narratives.

Equally important will be greater transparency across the value chain. Pet owners are becoming more sophisticated and more skeptical. They want to know where ingredients come from, how they are processed, why they are included, and what level of benefit can realistically be expected. Clear labeling, accessible scientific explanations, and honest communication about limitations will be critical to building trust and reducing confusion in a crowded marketplace.

Another key success factor will be closer integration with veterinarians and animal health professionals. Supplements that are positioned as complementary tools—rather than alternatives—to veterinary care are far more likely to gain long-term credibility. Veterinary endorsement, education, and involvement in study design can help align consumer expectations with real-world outcomes and elevate the overall standard of the category.

If one single change could most improve consumer trust over the next decade, it would be the establishment of clearer, more harmonized guidelines for claim substantiation and communication in pet supplements. This sits at the intersection of science, regulation, and education. Clearer frameworks around what constitutes adequate evidence for different types of claims—combined with consistent terminology and boundaries—would benefit all stakeholders. Consumers would gain clarity, responsible brands would be rewarded, and the industry as a whole would move away from exaggerated or ambiguous messaging.

Ultimately, trust in pet supplements will be earned not through bigger promises, but through better science, clearer communication, and a shared commitment to animal well-being.